Quest Diagnostics to Provide Diagnostic Testing Services for the Women of Ireland
News Jun 23, 2008
Women in Ireland will soon be able to take advantage of diagnostic testing services provided by Quest Diagnostics Incorporated. Through a contract with the Irish National Cancer Screening Service (NCSS), Quest Diagnostics will provide quality-assured screening services intended to improve medical outcomes and reduce anxiety wait time for women ages 25 to 60 who participate in Ireland's first nationwide cytology-screening program.
"Cervical cancer is a terrible disease that often strikes when a woman is in the prime of her life," said Ronald Kennedy, M.D., Corporate Medical Director, Quality Assurance in Anatomic Pathology, Quest Diagnostics.
"Our goal for this historic cytology-screening program is to ensure that Irish women experience the highest quality of testing and service excellence, with the goal of minimizing the incidence of cervical cancer. Our commitment to women's health, along with our industry leading quality-assurance practices, makes us imminently qualified to deliver the superior testing services that Irish women deserve."
Under the cytology-screening program, Quest Diagnostics will perform testing on approximately 300,000 Pap smears annually at two accredited, full-service laboratories in the U.S.
The company operates approximately 30 accredited full-service laboratories in the U.S. that could provide backup capabilities if required.
In addition, Quest Diagnostics will provide general practitioners and consultant colposcopists in Ireland with a toll-free phone number to consult with Quest Diagnostics' medical experts about a patient's test results.
"We applaud the NCSS for its commitment to developing a nationwide program designed to improve the health of women through regular cervical-cancer screening," said Kenneth R. Finnegan, Vice President, International, Quest Diagnostics. "We look forward to working with the NCSS and the entire medical community of Ireland to deliver world-class diagnostic services that enhance the health of Irish women."
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
New Drug Compounds Help Prevent Hearing LossNews
Researchers from St. Jude Children's Research Hospital have discovered that inhibiting an enzyme called cyclin-dependent kinase 2 (CDK2) protects mice and rats from noise- or drug-induced hearing loss. The study suggests that CDK2 inhibitors prevent the death of inner ear cells, which has the potential to save the hearing of millions of people around the world.READ MORE
Empowering Women in Technology Key to Boosting UK EconomyNews
A new report launched at London Stock Exchange for International Women’s Day, reveals the critical role women play in driving economic growth across the UK, with detailed research on 1,279 women-led companies showing a total contribution of £25.9 billion in revenue to the UK economy.READ MORE